Article

A three gene signature predicts response to selinexor in multiple myeloma

2022-02-26

Abstract excerpt

<h4>ABSTRACT</h4> Selinexor is the first selective inhibitor of nuclear export (SINE) to be approved for treatment of relapsed or refractory multiple myeloma (MM). There are currently no known genomic biomarkers or assays to help select MM patients at higher likelihood of response to selinexor. Here, we aim to characterize transcriptomic correlates of response to selinexor-based therapy, and present a novel, three...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 80cbf563-f810-5d09-bd2d-48b033614b77
DOI: 10.1101/2022.02.25.22271401

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A three gene signature predicts response to selinexor in multiple myelomaDOI 10.1101/2022.02.25.22271401Read

Functional transcriptomic landscape informs novel therapeutic strategies in multiple myelomaSemantic proximity Read

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity Read

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.Semantic proximity Read

High WEE1 expression is independently linked to poor survival in multiple myelomaSemantic proximity Read

Improved risk stratification in myeloma using a micro<scp>RNA</scp>‐based classifierSemantic proximity Read

ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.Semantic proximity Read

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome.Semantic proximity Read

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read

A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenibSemantic proximity Read

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes.Semantic proximity Read

Deep transcriptome profiling of multiple myeloma with quantitative measures using the SPECTRA approachSemantic proximity Read

A robust gene expression signature to predict proteasome inhibitor benefit in Multiple MyelomaSemantic proximity Read